WO2018232230A1 - Compositions and methods for inducing humoral and cellular immunities against tumors and cancer - Google Patents

Compositions and methods for inducing humoral and cellular immunities against tumors and cancer Download PDF

Info

Publication number
WO2018232230A1
WO2018232230A1 PCT/US2018/037737 US2018037737W WO2018232230A1 WO 2018232230 A1 WO2018232230 A1 WO 2018232230A1 US 2018037737 W US2018037737 W US 2018037737W WO 2018232230 A1 WO2018232230 A1 WO 2018232230A1
Authority
WO
WIPO (PCT)
Prior art keywords
gastrin
cancer
seq
tumor
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/037737
Other languages
English (en)
French (fr)
Inventor
Lynda SUTTON
Jill P. Smith
Nicholas Osborne
Brian E. Huber
Allen CATO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Advances Inc
Original Assignee
Cancer Advances Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3066756A priority Critical patent/CA3066756A1/en
Priority to EP18816949.4A priority patent/EP3624841A4/en
Priority to US16/622,841 priority patent/US11583576B2/en
Priority to CN201880053162.8A priority patent/CN111050789A/zh
Priority to AU2018283284A priority patent/AU2018283284B2/en
Priority to KR1020207001421A priority patent/KR102772810B1/ko
Priority to IL271427A priority patent/IL271427B2/en
Priority to JP2020519008A priority patent/JP7469225B2/ja
Application filed by Cancer Advances Inc filed Critical Cancer Advances Inc
Publication of WO2018232230A1 publication Critical patent/WO2018232230A1/en
Anticipated expiration legal-status Critical
Priority to US17/148,159 priority patent/US12150978B2/en
Priority to US18/056,843 priority patent/US12076383B2/en
Priority to JP2023216520A priority patent/JP2024038041A/ja
Priority to AU2024202846A priority patent/AU2024202846A1/en
Priority to US18/823,084 priority patent/US20250242007A1/en
Priority to US18/959,355 priority patent/US20250319171A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the first agent comprises a gastrin peptide, optionally a gastrin peptide comprising, consisting essentially of, or consisting of an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO: 1 ), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4).
  • EGPWLEEEEE SEQ ID NO: 1
  • EGPWLEEEE SEQ ID NO: 2
  • EGPWLEEEEEAY SEQ ID NO: 3
  • EGPWLEEEEEAYGWMDF SEQ ID NO: 4
  • the glutamic acid residue at amino acid 1 of any of SEQ ID NOs: 1 -4 is a pyroglutamate residue.
  • the first agent comprises an amount of a gastrin peptide comprising, consisting essentially of, or consisting of an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO: 1 ), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4) effective to induce an anti-gastrin humoral response and the second agent comprises an amount of an immune checkpoint inhibitor that is effective to induce or enhance a cellular immune response against a gastrin-associated tumor or cancer when administered to a subject who has gastrin-associated tumor or cancer.
  • the glutamic acid residue at amino acid 1 of any of SEQ ID NOs: 1 -4 is a pyroglutamate residue.
  • the methods comprise administering to the subject an effective amount of a composition that comprises a first agent that induces and/or provides an active and/or a passive humoral immune response against a gastrin peptide and/or a CCK-B receptor; and a second agent that induces and/or provides a cellular immune response against the gastrin-associated tumor or cancer.
  • the first agent is selected from the group consisting of a gastrin peptide, an anti-gastrin antibody, and an anti-CCK-R antibody.
  • the gastrin peptide is conjugated to an immunogenic carrier, optionally via a linker, which in some embodiments can be selected from the group consisting of diphtheria toxoid, tetanus toxoid, keyhole limpet hemocyanin, and bovine serum albumin.
  • the linker comprises a ⁇ -maleimido caproic acid N-hydroxysuccinamide ester.
  • the linker and the gastrin peptide are separated by an amino acid spacer, optionally wherein the amino acid spacer is between 1 and 10 amino acids in length, further optionally wherein the amino acid spacer is 7 amino acids in length.
  • the presently disclosed subject matter provides methods for inhibiting growth of a gastrin-associated tumor and/or cancer in a subject.
  • the methods comprise administering to the subject a composition that comprises a first agent comprising a gastrin immunogen, one or more anti-gastrin antibodies, one or more anti-CCK-B receptor antibodies, or any combination thereof; and a second agent comprising an immune checkpoint inhibitor.
  • the first agent is selected from the group consisting of a gastrin peptide, an anti-gastrin antibody, and an anti-CCK-R antibody.
  • the linker and the gastrin peptide are separated by an amino acid spacer, optionally wherein the amino acid spacer is between 1 and 10 amino acids in length, further optionally wherein the amino acid spacer is 7 amino acids in length.
  • methods employ a composition that further comprises an adjuvant, optionally an oil-based adjuvant.
  • the inducer of the cellular immune response against the gastrin-associated tumor or cancer comprises an immune checkpoint inhibitor.
  • the immune checkpoint inhibitor inhibits a biological activity of a target polypeptide selected from the group consisting of cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death-1 receptor (PD-1 ), and programmed cell death 1 receptor ligand (PD-L1 ).
  • CTLA4 cytotoxic T-lymphocyte antigen 4
  • PD-1 programmed cell death-1 receptor
  • PD-L1 programmed cell death 1 receptor ligand
  • the immune checkpoint inhibitor is selected from the group consisting of Ipilimumab, Tremelimumab, Nivolumab, Pidilizumab, Pembrolizumab, AMP514, AUNP12, BMS-936559/MDX-1 105, Atezolizumab, MPDL3280A, RG7446, R05541267, MEDI4736, Avelumab and Durvalumab.
  • compositions comprising an immune checkpoint inhibitor and a gastrin immunogen to treat a gastrin-associated tumor or cancer.
  • NP_032824.1 (Mus musculus), NP_001 100397.1 (Rattus norvegicus), NP_001301026.1 (Canis lupus familiaris), NP_001 138982.1 (Felis catus), NP_001076975.1 (Bos taurus), XP_004033550.1 (Gorilla gorilla gorilla), NP_001 107830.1 (Macaca mulatta), NP_001271065.1 (Macaca fascicularis), and XP_003776178.1 (Pongo abelii).
  • the ligand for the PD-1 receptor is referred to as the Programmed death- ligand 1 (PD-L1 ).
  • NP_033973.2 (Mus musculus), NP_1 13862.1 (Rattus norvegicus), NP_001003106.1 (Canis lupus familiaris), NP_001009236.1 (Felis catus), NP_776722.1 (Bos taurus), XP_004033133.1 (Gorilla gorilla gorilla), XP_009181095.2 (Macaca mulatta), XP_005574073.1 (Macaca fascicularis), and XP_526000.1 (Pan troglodytes).
  • PD-1 Nivolumab (OPDIVO® brand; Bristol-Myers Squibb, New York, New York), Pidilizumab (Medivation, San Francisco, California), Pembrolizumab (KEYTRUDA® brand; Merck & Co., Inc., Kenilworth, New Jersey), MEDI0680 (AMP514; Medimmune, LLC, Gaithersburg, Maryland), and AUNP-12 (Aurigene Discovery Technologies Limited/Laboratoires Pierre Fabre SA).
  • the linker and the gastrin peptide are separated by an amino acid spacer, optionally wherein the amino acid spacer is between 1 and 10 amino acids in length, further optionally wherein the amino acid spacer is 7 amino acids in length.
  • compositions of the presently disclosed subject matter that are designed to elicit humoral immune responses can in some embodiments further comprise an adjuvant, optionally an oil-based adjuvant.
  • adjuvants include but are not limited to montanide ISA-51 (Seppic, Inc.); QS-21 (Aquila Pharmaceuticals, Inc.); Arlacel A; oeleic acid; tetanus helper peptides; GM-CSF; cyclophosamide; bacillus Calmette-Guerin (BCG); corynbacterium parvum; levamisole, azimezone; isoprinisone; dinitrochlorobenezene (DNCB); keyhole limpet hemocyanins (KLH) including Freunds adjuvant (complete and incomplete); mineral gels; aluminum hydroxide (Alum); lysolecithin; pluronic polyols; polyanions; peptides; oil emulsions; nucleic acids (e.g., dsRNA)
  • compositions of the presently disclosed subject matter can in some embodiments comprise an immune checkpoint inhibitor.
  • Immune checkpoint inhibitors are a class of compounds that inhibits a biological activity of a target polypeptide selected from the group consisting of cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death-1 receptor (PD-1 ), and programmed cell death 1 receptor ligand (PD-L1 ).
  • CTLA4 cytotoxic T-lymphocyte antigen 4
  • PD-1 programmed cell death-1 receptor
  • PD-L1 programmed cell death 1 receptor ligand
  • small interfering RNA small interfering RNA
  • short interfering RNA small hairpin RNA
  • shRNA shRNA
  • RNA interference RNA interference
  • shRNA shRNA
  • RNAi RNA interference
  • Bass Nature 41 1 :428-429, 2001
  • Elbashir et al. Nature 41 1 :494-498, 2001 a
  • the siRNA comprises a single stranded polynucleotide having one or more loop structures and a stem comprising self- complementary sense and antisense regions, wherein the antisense region comprises a sequence complementary to a region of a target nucleic acid molecule, and wherein the polynucleotide can be processed either in vivo or in vitro to generate an active siRNA capable of mediating RNAi.
  • siRNA molecules need not be limited to those molecules containing only RNA, but further encompass chemically modified nucleotides and non-nucleotides.
  • the compositions can take the form of, for example, tablets or capsules prepared by a conventional technique with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycollate); or wetting agents (e.g., sodium lauryl sulfate).
  • binding agents e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g., magnesium stearate, talc or silica
  • disintegrants e.g.,
  • TEMRA cells are effector memory T cells that are found in the peripheral circulation and tissues. TEMRA cells appear to have a sentinel activity in that they might be involved in recognizing metastases. As such, increasing anti-gastrin TEMRA cells in subjects could prevent, reduce, and/or eliminate metastasis associated with gastrin-associated tumors and/or cancers. Therefore, in some embodiments the presently disclosed subject matter relates to methods for increasing TEMRA cells that recognize gastrin-associated tumor and/or cancer antigens and cells expressing the same by treating subjects with the pharmaceutical compositions disclosed herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PCT/US2018/037737 2017-06-15 2018-06-15 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer Ceased WO2018232230A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP2020519008A JP7469225B2 (ja) 2017-06-15 2018-06-15 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
EP18816949.4A EP3624841A4 (en) 2017-06-15 2018-06-15 COMPOSITIONS AND METHODS OF INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
US16/622,841 US11583576B2 (en) 2017-06-15 2018-06-15 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
CN201880053162.8A CN111050789A (zh) 2017-06-15 2018-06-15 用于诱导针对肿瘤和癌症的体液免疫和细胞免疫的组合物和方法
AU2018283284A AU2018283284B2 (en) 2017-06-15 2018-06-15 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
KR1020207001421A KR102772810B1 (ko) 2017-06-15 2018-06-15 종양 및 암에 대한 체액성 및 세포 면역을 유도하기 위한 조성물 및 방법
IL271427A IL271427B2 (en) 2017-06-15 2018-06-15 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
CA3066756A CA3066756A1 (en) 2017-06-15 2018-06-15 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US17/148,159 US12150978B2 (en) 2017-06-15 2021-01-13 Compositions and methods for preventing tumors and cancer
US18/056,843 US12076383B2 (en) 2017-06-15 2022-11-18 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
JP2023216520A JP2024038041A (ja) 2017-06-15 2023-12-22 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
AU2024202846A AU2024202846A1 (en) 2017-06-15 2024-05-01 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US18/823,084 US20250242007A1 (en) 2017-06-15 2024-09-03 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US18/959,355 US20250319171A1 (en) 2017-06-15 2024-11-25 Compositions and methods for preventing tumors and cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762520267P 2017-06-15 2017-06-15
US62/520,267 2017-06-15

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US16/622,841 A-371-Of-International US11583576B2 (en) 2017-06-15 2018-06-15 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US17/148,159 Continuation-In-Part US12150978B2 (en) 2017-06-15 2021-01-13 Compositions and methods for preventing tumors and cancer
US18/056,843 Division US12076383B2 (en) 2017-06-15 2022-11-18 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer

Publications (1)

Publication Number Publication Date
WO2018232230A1 true WO2018232230A1 (en) 2018-12-20

Family

ID=64659743

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/037737 Ceased WO2018232230A1 (en) 2017-06-15 2018-06-15 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer

Country Status (9)

Country Link
US (3) US11583576B2 (https=)
EP (1) EP3624841A4 (https=)
JP (2) JP7469225B2 (https=)
KR (1) KR102772810B1 (https=)
CN (1) CN111050789A (https=)
AU (2) AU2018283284B2 (https=)
CA (1) CA3066756A1 (https=)
IL (1) IL271427B2 (https=)
WO (1) WO2018232230A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230398196A1 (en) * 2020-11-06 2023-12-14 Cancer Advances Inc. Compositions and methods for enhancing t cell penetration of tumors and cancers
US12076383B2 (en) 2017-06-15 2024-09-03 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11725056B2 (en) * 2017-10-03 2023-08-15 Cedars-Sinai Medical Center Methods for targeting the immune checkpoint PD1 pathway for treating pulmonary fibrosis
WO2019110662A1 (en) * 2017-12-05 2019-06-13 Progastrine Et Cancers S.À R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
KR20230130722A (ko) * 2021-01-13 2023-09-12 캔서 어드밴시스 아이엔씨 종양 및 암 예방용 조성물 및 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091574A1 (en) * 2001-03-23 2003-05-15 Gevas Philip C. Combination treatment of pancreatic cancer
US20160228561A1 (en) * 2013-06-14 2016-08-11 Cansbio (Beijing) Biotechnology Co., Ltd. Protein-Cell Conjugate, Preparation Method and Use Thereof
US20160271239A1 (en) * 2013-11-05 2016-09-22 Bavarian Nordic A/S Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
WO2016196935A1 (en) * 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391141A (en) 1966-07-07 1968-07-02 Bristol Myers Co Synthetic cephalosporins
US4384995A (en) 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US5006334A (en) 1973-05-07 1991-04-09 The Ohio State University Antigenic modification of polypeptides
US4201770A (en) 1973-05-07 1980-05-06 The Ohio State University Antigenic modification of polypeptides
US4691006A (en) 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US4762913A (en) 1973-05-07 1988-08-09 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US4069313A (en) 1974-11-19 1978-01-17 Merck & Co., Inc. Water-in-oil adjuvant composition
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
SU1414392A1 (ru) 1982-12-29 1988-08-07 Всесоюзный кардиологический научный центр АМН СССР Противо звенное средство
US4925922A (en) 1983-02-22 1990-05-15 Xoma Corporation Potentiation of cytotoxic conjugates
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
CA1289077C (en) 1984-08-13 1991-09-17 Harry H. Leveen Treatment of cancer with phlorizin and its derivatives
FR2575164B1 (fr) 1984-12-20 1987-03-20 Sanofi Sa Esters de tri- et tetrapeptides inhibiteurs de la secretion gastrique, procede d'obtention et compositions pharmaceutiques les contenant
IT1179894B (it) 1984-12-27 1987-09-16 Rotta Research Lab Proglumide e composizioni farmaceutiche che la contengono per l impiego nella terapia di affezioni neoplastiche
US4803170A (en) 1985-05-09 1989-02-07 Ultra Diagnostics Corporation Competitive immunoassay method, device and test kit
US4713366A (en) 1985-12-04 1987-12-15 The Ohio State University Research Foundation Antigenic modification of polypeptides
IT1204430B (it) 1986-01-10 1989-03-01 Alfio Bertolini Composizioni farmaceutiche comprendenti peptidi del gruppo colecistochinina-cerulina per il trattamento terapeutico degli stati di shock e dell'insufficienza respiratoria e cardiocircolatoria
CA1341281C (en) 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5344919A (en) 1987-02-19 1994-09-06 The Scripps Research Institute Integrin from human epithelial cells
US4923819A (en) 1987-03-27 1990-05-08 Chimerix Corporation Time-resolved fluorescence immunoassay
US4971792A (en) 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
NZ227266A (en) 1987-12-09 1992-02-25 Gen Hospital Corp Method of detecting adenocarcinoma of colon, liver or lung by detecting the antigens af-20 and xf-8
US5035988A (en) 1988-05-12 1991-07-30 Fuji Photo Film Co., Ltd. Silver halide photographic material containing a yellow coupler and a phosphorus compound and color image forming method
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
JPH0249596A (ja) 1988-08-09 1990-02-19 Masamichi Ueda ヒト前立腺上皮細胞の表面に特異的に反応するモノクローナル抗体
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5759791A (en) 1989-01-17 1998-06-02 The Johns Hopkins University Cancer related antigen
US5023077A (en) 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
DK0380230T3 (da) 1989-01-24 1995-01-16 Aphton Corp Immunogene sammensætninger mod gastrin-peptider
US5120829A (en) 1989-03-20 1992-06-09 La Jolla Cancer Research Foundation Hydrophobic attachment site for adhesion peptides
US4997950A (en) 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5770576A (en) 1989-08-30 1998-06-23 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
US5164299A (en) 1990-03-20 1992-11-17 E. I. Du Pont De Nemours And Company Use of a mixture of conjugated and unconjugated solid phase binding reagent to enhance the performance of assays
US5932412A (en) 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
US5733790A (en) 1991-01-15 1998-03-31 The Salk Institute For Biological Studies CRF binding protein antibodies and assays using same
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5319073A (en) 1992-02-07 1994-06-07 The United States Of America, As Represented By The Department Of Health & Human Services Method of purifying cholecystokinin receptor protein
US5256542A (en) 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
CA2135277C (en) 1992-05-08 2001-04-24 Alton C. Morgan, Jr. Anti-receptor agents to the vitamin b12/transcobalamin ii receptor
US5639613A (en) 1992-05-13 1997-06-17 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
WO1994000590A1 (en) 1992-06-23 1994-01-06 The Mt. Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
US5736146A (en) 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
JP3439490B2 (ja) 1992-09-28 2003-08-25 株式会社林原生物化学研究所 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法
JP3628029B2 (ja) 1992-09-30 2005-03-09 塩野義製薬株式会社 ガストリン拮抗剤の新用途
AU679902B2 (en) 1992-09-30 1997-07-17 Ohio State University Research Foundation, The Vaccines and antigenic conjugates
US5879898A (en) 1992-11-20 1999-03-09 Isis Innovation Limited Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors
US5683695A (en) 1993-02-10 1997-11-04 United Biomedical, Inc. Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
KR100340091B1 (ko) 1993-08-09 2002-09-27 베르찌 이스트반 킬러세포개재세포용해를위한암세포감작용약학적제제
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5468494A (en) 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
ATE464315T1 (de) 1994-01-14 2010-04-15 Rath Matthias Dr Med Hydrophile signal-oligopeptide und verfahren der therapeutischen anwendung
US7300918B2 (en) 1994-01-14 2007-11-27 Matthias Rath Method of producing vaccines from protein signal oligopeptides
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995021380A1 (en) 1994-02-02 1995-08-10 Ludwig Institute For Cancer Research Assay for screening of receptor antagonists
US5767242A (en) 1994-04-20 1998-06-16 Boehringer Ingelheim Int'l Gmbh Isolated dimeric fibroblast activation protein alpha, and uses thereof
US5869058A (en) 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
DE59511054D1 (de) 1994-07-25 2006-08-10 Roche Diagnostics Gmbh Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene
JP3853384B2 (ja) 1994-09-09 2006-12-06 株式会社三菱化学ヤトロン 抗サイモシンα１モノクローナル抗体産生ハイブリドーマ
US5789000A (en) 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
FI97304C (fi) 1994-11-16 1996-11-25 Locus Genex Oy Menetelmä mahasyövän riskin seulonnaksi
US5723718A (en) 1994-12-20 1998-03-03 St. Joseph's Hospital And Medical Center Induction of immune tolerance to tumor cells
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US7078493B1 (en) 1995-03-15 2006-07-18 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like genes
WO1996035806A1 (en) 1995-05-12 1996-11-14 Schering Corporation Surface plasmon resonance based enzymatic assay
US6359114B1 (en) 1995-06-07 2002-03-19 Aphton Corp. System for method for the modification and purification of proteins
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5712369A (en) 1995-08-24 1998-01-27 Ludwig Institute For Cancer Research Isolated protein which binds to A33 antibody, and peptides corresponding to portions of the protein
DE69602756T2 (de) 1995-08-18 2000-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
ES2361474T3 (es) 1996-02-08 2011-06-17 Cancer Advances, Inc. Procedimientos inmunológicos para el tratamiento del cáncer gastrointestinal.
US5786213A (en) 1996-04-18 1998-07-28 Board Of Regents, The University Of Texas System Inhibition of endogenous gastrin expression for treatment of colorectal cancer
AU2978697A (en) 1996-06-07 1998-01-05 Takeda Chemical Industries Ltd. Novel peptide, process for the production of the same, and use of the same
IL118626A0 (en) 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
JPH1026621A (ja) 1996-07-12 1998-01-27 Dai Ichi Pure Chem Co Ltd イムノアッセイ法
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US6472506B1 (en) 1997-01-21 2002-10-29 Aventis Pasteur S.A. Polysaccharide-peptide-conjugates
AU6659298A (en) 1997-02-18 1998-09-08 Thomas Jefferson University Compositions that bind to pancreatic cancer cells and methods of using the same
HUP0002760A3 (en) 1997-05-12 2003-03-28 Aphton Corp Woodland Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
US20040001842A1 (en) 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
AUPO982097A0 (en) 1997-10-15 1997-11-06 University Of Melbourne, The Methods and compositions for use therein
EP1060022A1 (en) 1998-02-04 2000-12-20 Merck & Co., Inc. Virtual wells for use in high throughput screening assays
US20030068326A1 (en) 1998-05-15 2003-04-10 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
CA2328501A1 (en) 1998-05-15 1999-11-25 Aphton Corporation Prevention and treatment of hypergastrinemia
EP1076561B1 (en) 1998-05-15 2005-03-30 Aphton Corporation Combination therapy for the treatment of tumors
EP1579863A3 (en) 1998-05-15 2008-03-19 Receptor Biologix, Inc. Combination therapy with anti-gastrin G17 antibodies for the treatment of tumors
AU768612B2 (en) 1998-06-18 2003-12-18 Vecta Ltd Pharmaceutical compositions for the treatment of (helicobacter pylori)-associated disorders
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
MXPA01008699A (es) 1999-02-24 2002-06-21 Uab Research Foundation Derivados de taxano para terapia de cancer dirigida. .
FI118653B (fi) 1999-04-30 2008-01-31 Biohit Oyj Menetelmä peptisen haavan riskin määrittämiseksi
FR2797689B1 (fr) 1999-08-16 2003-06-27 Pasteur Sanofi Diagnostics Utilisation de composes synthetiques pour des immunodosages
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
AU1478201A (en) 1999-11-08 2001-06-06 Aphton Corporation Improved method of immunization
WO2001045670A2 (en) 1999-12-23 2001-06-28 Aphton Corporation A stable immunogenic composition for frozen storage
CA2404852A1 (en) 2000-04-10 2001-10-18 Timothy C. Wang Diagnosis and treatment of gastrointestinal disease
US20030232399A1 (en) 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US20030138860A1 (en) 2000-06-14 2003-07-24 Robertson John Forsyth Russell Cancer detection methods and reagents
US6780969B2 (en) 2000-12-22 2004-08-24 United Biomedical, Inc. Synthetic peptide composition as immunogens for prevention of urinary tract infection
NZ527977A (en) 2001-02-12 2005-10-28 Medarex Inc Human monoclonal antibodies to FC alpha receptor (CD89)
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US20030021786A1 (en) 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
PT2308888T (pt) 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US20040247661A1 (en) 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
WO2004004687A2 (en) 2002-07-03 2004-01-15 Aphton Corporation Liposomal vaccine
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US20050169979A1 (en) 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
FI119571B (fi) 2002-09-06 2008-12-31 Biohit Oyj Menetelmä esofagiitin tai Barrettin ruokatorven riskin osoittamiseksi yksilöllä
US20030049698A1 (en) 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
WO2004088326A2 (en) 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
US20060020119A1 (en) 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
US20070031511A1 (en) 2003-04-08 2007-02-08 Baldwin Graham S Method of treatment
CN1997669A (zh) 2004-03-29 2007-07-11 受体生物技术公司 抗胃泌素激素单克隆抗体
WO2006008649A1 (en) 2004-07-15 2006-01-26 Aphton Corporation Anti-sense polynucleotide therapy for gastrin-promoted tumors
AU2005270917A1 (en) 2004-08-11 2006-02-16 Cancer Advances, Inc. Gastrin-specific interfering RNA
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
DK1794586T3 (da) 2004-09-22 2013-05-13 Cancer Advances Inc Monoklonale antistoffer til progastrin
EP1971363A1 (en) 2005-12-02 2008-09-24 Waratah Pharmaceuticals, Inc. Combination treatments with gastrin agonists for diabetes and related diseases
CN100558747C (zh) * 2006-04-06 2009-11-11 海南天源康泽医药科技有限公司 以白喉毒素突变体crm197为载体的免疫原及其制备方法与应用
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
EP2482849B1 (en) 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
GB201121571D0 (en) 2011-12-15 2012-01-25 Astrimmune Ltd Compounds and uses thereof
EP2999485B1 (en) 2013-05-21 2018-01-31 Tyg Oncology Ltd. Gastrin peptide immunogenic composition
EP3624841A4 (en) 2017-06-15 2021-01-27 Cancer Advances, Inc., COMPOSITIONS AND METHODS OF INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
KR20230130722A (ko) 2021-01-13 2023-09-12 캔서 어드밴시스 아이엔씨 종양 및 암 예방용 조성물 및 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091574A1 (en) * 2001-03-23 2003-05-15 Gevas Philip C. Combination treatment of pancreatic cancer
US20160228561A1 (en) * 2013-06-14 2016-08-11 Cansbio (Beijing) Biotechnology Co., Ltd. Protein-Cell Conjugate, Preparation Method and Use Thereof
US20160271239A1 (en) * 2013-11-05 2016-09-22 Bavarian Nordic A/S Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
WO2016196935A1 (en) * 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3624841A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12076383B2 (en) 2017-06-15 2024-09-03 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
US20230398196A1 (en) * 2020-11-06 2023-12-14 Cancer Advances Inc. Compositions and methods for enhancing t cell penetration of tumors and cancers

Also Published As

Publication number Publication date
US20230086898A1 (en) 2023-03-23
JP2020528449A (ja) 2020-09-24
AU2018283284B2 (en) 2024-05-16
EP3624841A4 (en) 2021-01-27
CN111050789A (zh) 2020-04-21
KR102772810B1 (ko) 2025-02-28
JP2024038041A (ja) 2024-03-19
JP7469225B2 (ja) 2024-04-16
US11583576B2 (en) 2023-02-21
EP3624841A1 (en) 2020-03-25
CA3066756A1 (en) 2018-12-20
US12076383B2 (en) 2024-09-03
IL271427B2 (en) 2025-08-01
AU2024202846A1 (en) 2024-05-23
IL271427A (en) 2020-01-30
US20200206332A1 (en) 2020-07-02
US20250242007A1 (en) 2025-07-31
AU2018283284A1 (en) 2020-01-30
KR20200015943A (ko) 2020-02-13
IL271427B1 (en) 2025-04-01

Similar Documents

Publication Publication Date Title
US12076383B2 (en) Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
Dougan et al. Immune therapy for cancer
US20260116986A1 (en) Epo receptor agonists and antagonists
US20240398917A1 (en) Compositions and methods for preventing tumors and cancer
US20250319171A1 (en) Compositions and methods for preventing tumors and cancer
AU2021373880B2 (en) Compositions and methods for enhancing t cell penetration of tumors and cancers
US20210340232A1 (en) Monoclonal antibodies against human dickkopf3 and uses thereof
KR20240109616A (ko) 폐암에 대한 치료학적 rna
US9795660B2 (en) Id-protein targeted tumor cell vaccine
US20250032543A1 (en) Dual targeting of pediatric malignancies through car t-cells secreting bispecific innate immune cell engagers (bices)
WO2025120867A1 (en) Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025179135A1 (en) Methods and compositions for treating cancer using targeted pore-forming agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18816949

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 3066756

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020519008

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20207001421

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018816949

Country of ref document: EP

Effective date: 20191219

ENP Entry into the national phase

Ref document number: 2018283284

Country of ref document: AU

Date of ref document: 20180615

Kind code of ref document: A